Rebyota denied as duplicate or overlapping therapy by Cigna?
If two medications appear duplicative on paper but serve different clinical purposes (e.g., short-acting vs long-acting), the appeal needs to spell out the clinical rationale for both.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Cigna typically requires
Cigna's specific coverage criteria for rebyota are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Cigna angle on Rebyota
## Why Cigna Denied Rebyota as Duplicate Therapy — and Why You Can Appeal
Rebyota (fecal microbiota, live-jslm) is an FDA-approved microbiome-based therapy specifically indicated to prevent recurrence of Clostridioides difficile (C. diff) infection following standard antibiotic treatment. A duplicate-therapy denial means Cigna's system flagged an existing or concurrent prescription — typically a different antibiotic or, in some cases, another microbiome product — as serving the same clinical purpose. This automated comparison often misses the clinical distinction between treating an active C. diff infection and preventing its recurrence, which is the specific, distinct indication for Rebyota.
## Why This Denial Is Appealable
Duplicate-therapy logic is applied algorithmically and frequently generates false positives when two agents address different phases of the same disease. Rebyota's FDA-approved indication is the prevention of recurrence — not the treatment of active infection. If the "duplicate" identified by Cigna is an antibiotic used to clear the active infection, there is no true therapeutic overlap: the antibiotic addresses active disease and Rebyota addresses recurrence prevention, making them complementary rather than duplicative. Your prescriber can document this distinction clearly.
## Federal Appeal Framework
- Internal appeal: File within the timeframe stated on the denial notice. For ERISA employer plans, ERISA Section 503 requires a full-and-fair review with access to the specific clinical criteria used.
- ACA Section 2719 external review: Available for non-grandfathered plans after exhausting internal remedies. The standard external-review window is approximately 4 months from the final internal denial.
- Expedited review: If recurrent C. diff poses an urgent health risk in your case, request expedited processing.
## Appeal Timeline
1. Request the specific drug or therapy Cigna identified as the duplicate. 2. Have your prescriber document why the two therapies serve different clinical purposes. 3. File the internal appeal with supporting records. 4. If internally denied, file for external review promptly.
## Documentation to Gather
- Diagnosis records: Documentation of recurrent C. diff infection history with episode dates.
- Treatment history: Records of all prior C. diff treatment courses, including the antibiotic(s) used and outcomes.
- Prescriber medical-necessity letter: Should explain that Rebyota serves a distinct clinical purpose (recurrence prevention) from any concurrent antibiotic therapy, and that the two therapies do not duplicate each other per the FDA-approved prescribing label.
- FDA labeling reference: Your prescriber should note Rebyota's specific approved indication as distinct from the identified "duplicate."
## Criteria-Mapping Structure
Obtain Cigna's coverage policy for Rebyota and its duplicate-therapy criteria. Map each element:
| Cigna Criterion | Supporting Documentation | |---|---| | Confirmed distinct indication from the identified duplicate | Prescriber letter; FDA label for each product | | History of recurrent C. diff meeting coverage criteria | Episode dates and treatment records | | Concurrent therapy serves a different clinical purpose | Clinical notes and specialist attestation |
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →